Is the platform is in the skincare I thought lot was in the skincare?
In the skincare, we do not have any candidates in skincare at this time.
First of all, it’s ingredients in the skincare all the time, right?
Probably not exactly we’re talking about here. I go into that platform in the next few slides that’s an interesting question now. Okay, now we are not just a platform company, we are also a product company we have a fairly robust for these (inaudible) company product pipeline, for peptide-drug conjugates our PDCs our first candidate or first PDC is called a dipeptide its against obesity. We have begun in Phase I study at MD Anderson Cancer Center about a month ago and so we are dosing patients as we speak. We also have a generic conjugate program in oncology that we are developing that’s still preclinical with in targeted RNAi, we have CALAA-01, which is an oncology, it’s a solid tumor, RNAi therapeutic, we’re finishing the Phase Ib in the next couple of weeks. Our next RNAi therapeutics is called ARC-520 that is again hepatitis B and we believe that we can file an IND in the second quarter of 2013. And we also have follow-on programs within our RNAi program, RNAi platforms probably the most advanced is against renal cell carcinoma.
Now I’ve got these two hepatitis in ARC-520 because read we think that those are potentially attractive to partners early. And the reason is because they’re both serving or addressing large underserved markets, we got very [contaminant] preclinical data in both we got unique amount of action in both, and we’ll talk about that in next several slides. And the trials are designed to provide early efficacy signals in both of those.
Read the rest of this transcript for free on seekingalpha.com